Serum-circulating miRNAs predict neuroblastoma progression in mouse model of high-risk metastatic disease

@article{Ramraj2016SerumcirculatingMP,
  title={Serum-circulating miRNAs predict neuroblastoma progression in mouse model of high-risk metastatic disease},
  author={Satish Kumar Ramraj and Sheeja Aravindan and Dinesh Babu Somasundaram and Terence S Herman and Mohan Natarajan and Natarajan Aravindan},
  journal={Oncotarget},
  year={2016},
  volume={7},
  pages={18605 - 18619}
}
Background Circulating miRNAs have momentous clinical relevance as prognostic biomarkers and in the progression of solid tumors. Recognizing novel candidates of neuroblastoma-specific circulating miRNAs would allow us to identify potential prognostic biomarkers that could predict the switch from favorable to high-risk metastatic neuroblastoma (HR-NB). Results Utilizing mouse models of favorable and HR-NB and whole miRnome profiling, we identified high serum levels of 34 and low levels of 46… Expand
Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients
TLDR
Evaluation of serum miRNA variance in a model testing for tumor stage, MYCN status, age at diagnosis and overall survival, revealed tumor stage as the most significant factor impacting miRNA abundance in neuroblastoma serum. Expand
Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients.
TLDR
Evaluation of serum miRNA variance in a model testing for tumor stage, MYCN status, age at diagnosis, and overall survival revealed tumor stage as the most significant factor impacting miRNA abundance in neuroblastoma serum. Expand
GD2‐targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma
TLDR
Various biomarkers involved in diagnosis, prognosis and response to treatment in patients with NB are summarized and prognostic biomarkers in response toreatment with anti‐GD2 drugs are overviewed. Expand
MicroRNA dysregulation interplay with childhood abdominal tumors
TLDR
The present study was undertaken to compile up-to-date information regarding the role of dysregulated miRNAs in the most common histological variants of AT, including neuroblastoma, nephroblastomas, hepatoblastoma, hepatocarcinoma, and adrenal tumors. Expand
Towards diagnostic application of non-coding RNAs in neuroblastoma
TLDR
Here, a focus is placed on miRNAs that have been linked to MYCN, a prominent oncogenic driver, and the hitherto known interactions between mi RNAs and other important players in neuroblastoma. Expand
Emerging therapeutic targets for neuroblastoma
TLDR
Fittingly, the looming evidence indicated an aggressive evolution of promising novel and integrative targets, development of efficient drugs, and improvised strategies for HR-NB treatment. Expand
MiRNA Influences in Neuroblast Modulation: An Introspective Analysis
TLDR
T thorough understanding of the mechanisms of how these miRNAs interplay at the transcriptomic level will definitely lead to the development of novel, bespoke and efficient therapeutic measures, with this review focusing on the influences of mi RNAs on neuroblast modulations leading to neuroblastoma. Expand
Nanotechnologoical based miRNA intervention in the therapeutic management of neuroblastoma.
TLDR
The nanoformulated miRNAs unload anti-cancer drugs in a controlled and prespecified manner at target sites, to influence the activity of target protein in amelioration of NB. Expand
Circular RNA hsa_circ_0072309 inhibits non-small cell lung cancer progression by sponging miR-580-3p
TLDR
Findings revealed the anti-tumor role of circ_0072309 during the development of NSCLC and provided a novel diagnostic biomarker and potential therapy forNSCLC. Expand
De novo regulation of RD3 synthesis in residual neuroblastoma cells after intensive multi-modal clinical therapy harmonizes disease evolution
TLDR
Whether RD3 loss is an acquired process in cells that survive intensive multi-modal clinical therapy (IMCT) and its significance in disease evolution is investigated and profound reductions in RD3 transcription indicate the de novo regulation of RD3 synthesis in resistant cells after IMCT. Expand
...
1
2
...

References

SHOWING 1-10 OF 50 REFERENCES
Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease.
TLDR
These findings suggest that individual cancers display specific systemic miRNA profiles, which could aid in discriminating among cancer types, and illustrate the potential of systemic miRNAs as sensitive, specific, noninvasive cancer biomarkers. Expand
Deep sequencing reveals differential expression of microRNAs in favorable versus unfavorable neuroblastoma
TLDR
In-depth sequence analysis revealed extensive post-transcriptional miRNA editing in Neuroblastoma patients, and the putative tumor suppressive microRNAs, miR-542-5p and mi-628, were expressed in favorable NBs and virtually absent in unfavorable NBs. Expand
Circulating microRNAs as stable blood-based markers for cancer detection
TLDR
It is shown here that miRNAs are present in human plasma in a remarkably stable form that is protected from endogenous RNase activity and established the measurement of tumor-derived mi RNAs in serum or plasma as an important approach for the blood-based detection of human cancer. Expand
Cell-free Circulating miRNA Biomarkers in Cancer
TLDR
The clinical use and function of potentially promising miRNA biomarkers in a variety of different cancers, along with their downstream target genes in tumor initiation and development are summarized. Expand
Reorganization of metastamiRs in the evolution of metastatic aggressive neuroblastoma cells
TLDR
For the first time, these results identified a comprehensive list of neuroblastoma metastamiRs, related their deregulation to altered expression of protein targets, and established their association with poor clinical outcomes. Expand
Low Levels of Cell-Free Circulating miR-361-3p and miR-625* as Blood-Based Markers for Discriminating Malignant from Benign Lung Tumors
TLDR
Blood-based microarray profiling of microRNA (miR) expression was performed in preoperative serum of non-small cell lung cancer (NSCLC) patients and 11 healthy individuals, and quantitative assessment of these miRs in blood serum might have diagnostic potential to detect NSCLC, in particular in smokers. Expand
The Role of MicroRNAs in Ovarian Cancer
TLDR
Although many obstacles need to be overcome, microRNA therapy could be a powerful tool for ovarian cancer prevention and treatment, and several microRNA signatures that are unique to ovarian cancer have the potential to be useful diagnostic and prognostic biomarkers. Expand
Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model
TLDR
It is shown that systemic treatment of tumor-bearing mice with miR-10b antagomirs—a class of chemically modified anti-miRNA oligonucleotide—suppresses breast cancer metastasis and appears to be a promising candidate for the development of new anti-metastasis agents. Expand
Clinical Aspect of MicroRNA in Lung Cancer
  • H. Jeong
  • Medicine
  • Tuberculosis and respiratory diseases
  • 2014
TLDR
Recent researches regarding clinical applications of miRNAs in the diagnosis and management of lung cancer are summarized. Expand
Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (review).
TLDR
The role of circulating miRNAs could be particularly relevant in the context of neoplastic diseases, and the profiling of alterations in circulating miRNA that may signal a predisposition to cancer, could also be a therapeutic target in these patients. Expand
...
1
2
3
4
5
...